Grant of Awards

RNS Number : 1108T

Allergy Therapeutics PLC

30 December 2016

 

30 December 2016

Allergy Therapeutics plc

("Allergy Therapeutics" or the 'Company")

Grant of Awards under Long Term Incentive Plan

Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that, pursuant to the Company's Long Term Incentive Plan ("LTIP") the following conditional awards of shares of 0.1 pence each were made to Executive Directors at nominal cost of 0.1 pence each on 30 December 2016.

Executive Director	Number of Conditional shares awarded	Total conditional shares held under LTIPs
Manuel Llobet	1,690,000	3,380,000
Nick Wykeman	422,500	422,500

The issuance and distribution of ordinary shares of 0.1 pence each under the LTIP is conditional on the satisfaction of performance conditions which include an earnings growth test over a three year testing period to 30 June 2019 and share price growth over the 3 year plan cycle.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Manuel Llobet Nicolas Wykeman
2	Reason for the notification Grant of conditional awards of 0.1 pence each
a)	Position/status	Manual Llobet - Chief Executive Office Nicolas Wykeman - Finance Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ALLERGY THERAPEUTICS PLC
b)	LEI
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Conditional award of shares under the Company's Long Term Incentive Plan
b)	Nature of the transaction
c)	Price(s) and volume(s)	1,690,000
d)	Aggregated information - Aggregated volume - Price
e)	Date of the transaction	30 December 2016
f)	Place of the transaction	Outside a trading venue

Name of authorised official of issuer responsible for making notification:

Allergy Therapeutics [phone]
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon [phone] Freddy Crossley / Duncan Monteith, Corporate Finance Tom Salvesen, Corporate Broking
Consilium Strategic Communications [phone] Mary-Jane Elliott / Ivar Milligan [e-mail]

Note to editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease.  The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities.  The Company employs c.420 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

 

END

 

 

DSHZBLFXQLFLFBD